We also observed dose-dependent enhancement of tumor cell killing with increasing concentrations of recombinant huIL12, which resulted in increased production of IFNγ by CAR T cells as determined by ELISA at the assay endpoint (Fig. 2b, right, and 2c). Here, IFNG is linked to neoplasm.